News

The Clinical and Laboratory Standards Institute (CLSI) is pleased to announce its 2024 Board of Directors.

Clinical and Laboratory Standards Institute (CLSI) is pleased to announce that it has been awarded a Power of Associations Gold Award from the American Society of Association Executives (ASAE) for CLSI’s successful global #MicroFree program.

A 60-year-old female with a history of colon cancer presented to the Emergency Department with acute onset of abdominal pain. She had a recent proctocolectomy (removal of rectum and part of colon). Her temperature was normal, blood pressure was 136/70, and heart rate was 149 beats per minute.

Major changes to the aminoglycoside (gentamicin, tobramycin, and amikacin) breakpoints were published in CLSI M100-Ed33.

A 45-year-old patient with acute myeloid leukemia (AML) received induction chemotherapy 2 weeks ago and currently has an absolute neutrophil count of <100 cells/μL. The patient had been on levofloxacin prophylaxis for his neutropenia, but developed a fever a week ago, at which point meropenem was started. All cultures and imaging were negative.

In the July 2020 issue of this News Update, cefiderocol (trade name Fetroja®, manufactured by Shionogi) was discussed to include its projected use, requirements for testing, and more. Since that time, several new developments have occurred for cefiderocol testing.

M24S includes the minimal inhibitory concentrations and QC ranges developed following the standards described in CLSI document M24, which includes susceptibility testing procedures for Mycobacterium tuberculosis complex (MTBC), clinically significant slowly and rapidly growing mycobacterial species, Nocardia spp., and other aerobic actinomycetes.

Malvern, Pennsylvania, USA—The Clinical and Laboratory Standards Institute (CLSI) has published CLSI EP12—Evaluation of Qualitative, Binary Output Examination Performance, 3rd Ed.

CLSI has published M100—Performance Standards for Antimicrobial Susceptibility Testing, 33rd Edition. The tables presented in M100 represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in CLSI documents M02, M07, and M11. This document is intended for use by microbiology labs, antimicrobial stewardship teams, infectious disease experts, and other relevant stakeholders intending to provide optimal patent care using the most up-to-date antimicrobial susceptibility breakpoints and test methods. To ensure the correct use of the document, users should replace previously published tables with the new edition immediately.

The Clinical and Laboratory Standards Institute announces the recipients of its 2023 Excellence Awards. These awards celebrate the achievements of CLSI volunteers and organizational members who are committed to CLSI’s mission and have helped improve the quality of medical care worldwide. Recipients are recognized for dedicating significant time and effort to the development, implementation, and promotion of CLSI standards.